SCLC transcription factors coexist intratumorally and undergo phenotypic switching under microenvironmental regulation—e.g., chemotherapy or ASCL1-targeted therapy enriches NEUROD1/POU2F3-positive cells, causing drug resistance and recurrence. Here, NEUROD1 is linked to small cell lung carcinoma.